Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California. Show more
Location: 200 Penobscot Drive, Redwood City, CA, 94063, United States | Website: https://www.codexis.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
219.4M
52 Wk Range
$1.90 - $6.08
Previous Close
$2.43
Open
$2.44
Volume
305,847
Day Range
$2.38 - $2.46
Enterprise Value
222M
Cash
66.33M
Avg Qtr Burn
-15.3M
Insider Ownership
2.29%
Institutional Own.
80.74%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|